SLUG expression is an indicator of tumour recurrence in high-grade endometrial carcinomas
Autor: | Toshiro Kubota, Kimio Wakana, Atsushi Kihara, Masanobu Kitagawa |
---|---|
Rok vydání: | 2016 |
Předmět: |
Adult
0301 basic medicine Oncology medicine.medical_specialty Histology Serous carcinoma Slug Kaplan-Meier Estimate Snail Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine biology.animal Internal medicine Biomarkers Tumor medicine Adjuvant therapy Carcinoma Humans Aged Proportional Hazards Models biology business.industry fungi Hazard ratio General Medicine Middle Aged Prognosis medicine.disease biology.organism_classification Immunohistochemistry Endometrial Neoplasms 030104 developmental biology 030220 oncology & carcinogenesis Clear cell carcinoma Female Snail Family Transcription Factors Neoplasm Grading Neoplasm Recurrence Local business |
Zdroj: | Histopathology. 69:374-382 |
ISSN: | 0309-0167 |
Popis: | Aims To investigate how SNAIL and SLUG were involved in the nature of high-grade endometrial carcinomas (grade 3 endometrioid carcinoma, serous carcinoma and clear cell carcinoma), we analysed the correlation of their expression status with clinicopathological characteristics and evaluated their prognostic significance. Methods and results We performed immunohistochemical staining in 52 high-grade endometrial carcinomas. Expression status of SNAIL and SLUG was classified into a high expression (positive in more than 50% of the tumour cells) and a low expression. Thirteen cases (25%) showed a high expression of SLUG, whereas all 52 cases showed a low expression of SNAIL. High expression of SLUG was correlated significantly with tumour recurrence (P = 0.0203) and aberrant p53 expression (P = 0.000559). Overall survival was worse in patients with high SLUG expression at all stages (P = 0.0327) and in those who underwent adjuvant therapy (P = 0.00963). Among the patients with complete tumour resection, high SLUG expression was associated with worse recurrence-free survival (RFS) in the patients at all stages (P = 0.00264), at stages III/IV (P = 0.0146), and who underwent adjuvant therapy (P = 0.000743). SLUG expression was identified as an independent factor of RFS by multivariate analysis (hazard ratio 5.938, 95% confidence interval 1.251–28.18, P = 0.025). Conclusions SLUG expression could be correlated with TP53 mutational status and could be involved in therapeutic resistance resulting in tumour recurrence. A high expression level of SLUG can be an indicator of recurrence and a therapeutic target for long-term remission in high-grade endometrial carcinomas. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |